8 results on '"Mclelland, V"'
Search Results
2. INTRODUCTION
- Author
-
Muscedere, John, Bebenek, Sarah Grace, Stockley, Denise, Kinderman, Laura, Barrie, Carol, Salim, S., Warkentin, L., Gallivan, A., Churchill, T., Baracos, V., Khadaroo, R., McCullough, J., Keller, H., Vesnaver, E., Marcus, H., Lister, T., Nasser, R., Belley, L., Laur, C., Gainer, R., Moorhouse, P., Mallery, L., Hirsch, G., Hamilton, G., Wheeler, K., Di Michelle, J., Lalu, M.M, McIsaac, D. I, Mallery, K., Theou, O., Goldstein, J., Armstrong, J., Webb, J., Greene, J., Doyle, E., Douglas, B., Lee, J., Rockwood, K., Whitty, R., Koo, E., Porter, S., Battu, K., Kalocsai, C., Reid, J., Kho, M., Molloy, A., Herridge, M. S, Karachi, T., Fox-Robichaud, A., Koo, K. KY, Lo, V., Mathur, S., McCaughan, M., Pellizzari, J., Rudkowski, J., Figueiredo, S., Morais, J., Mayo, N., Meffen, K., Penner, C., Meyyappan, R., Sandoval, R., Broderick, J., Hoffer, A., Chambers, S., Ball, I., Martin, C., Awan, S., Rajji, T., Uranis, C., Kim, D., Burhan, A., Ting, R., Ito, H., Graff, A., Gerretsen, P., Woo, V., Mulsant, B., Davies, S., Paul, L. Read, Spice, R., Sinnarajah, A., Ho, G., Webb, M., Uniacke, J., Linsey, J., Kettle, J., Salmon, C., Mohammed, R., Whitby, C., Cowie, B., Wang, S., Sawatzky, R., Chan, E., Wolfs, D., Harding, W., Laforest, E., Schick-Makaroff, K., King, G., Cohen, S. R., Neufeld, C., Lett, J., Voth, J., Durepos, P., Wickson-Griffiths, A., Hazzan, A. Abiola, Kaasalainen, S., Vastis, V., Battistella, L., Papaioannou, A., Asselin, G., Klein, D., Tan, A., Kendell, C., Burge, F., Kotecha, J., Marshall, E., Cash, C., Tschupruk, C., Urquhart, R., Cottrell, L., Erbacker, L., Pesut, B., Duggleby, W., Bui, M., Te, A., Brazil, E., Sussman, T., Team, SPA-LTC, Delicaet, K., MacDonald, J., Hartwick, M., des Ordons, A. Roze, Myers, J., Pereira, J., Simon, J., Abdul-Razzak, A., Sharma, A., Ogilvie, L., Downar, J., Choukou, M.A., Holroyd-Leduc, J. M., Kazanjian, A., Durand, P. J, Straus, S. E, Légaré, F., Turgeon, A. F., Tourigny, A., Dumont, S., Mc Giguere, A., Lounsbury, K., Friesen, D., Bitschy, A., Donald, E. E, Stajduhar, K., Knapp, A., Klinger, C., Wentlandt, K., Urowitz, S., Walton, T., Chahal, M., Zwicker, V., Cohen, T., Morales, M. López, Miller, K., Duggan, K., Barnett-Cowan, M., Kortes-Miller, K., Kelley, M. Lou, Nayfeh, A., Marcoux, I., Jutai, J., Virag, O., Khakoo, A., Incardona, N., Workentin, K., Maxwell, C., Stock, K., Hogan, D. B., Tyas, S. L., Bronskill, S. E., Morris, A. M., Bell, C. M., Jeffs, L., Gandhi, S., Blain, J., Toubasi, S., Andrew, M., Ashe, M., Atkinson, E., Ayala, A. P., Bergman, H., Ploeg, J., McGilton, K., Patten, S. B., Maxwell, C. J., Delleman, B., Chan, D., Siu, H., Howard, M., Mangin, D., Akioyamen, L., Hoben, M., Estabrooks, C., McArthur, C., Gibbs, J. C., Patel, R., Neves, P., Killingbeck, J., Hirdes, J., Milligan, J., Berg, K., Giangreogrio, L., Adekpedjou, R., Stacey, D., Brière, N., Freitas, A., Marjolein, M., Garvelink, Turcotte, S., Heyer, M., Boscart, V., Heckman, G., Zahradnik, M., Jeffs, L. P., Mainville, C., Maione, M., Morris, A., Bell, C., Bronskill, S., Tscheng, D., Sever, L., Hyland, S., Emond, J., Garvelink, M., Menear, M., MacLeod, T., LeBlanc, C., Allen, M., McLean-Veysey, P., Rodney-Cail, N., Steeves, B., Bezanson, E., Van Ooteghem, K., Trinh, A., Cowan, D., Kwok, L., Fels, D., Meza, M., Fels-Leung, S., Ouellette-Kuntz, H., McKenzie, K., Martin, L., Bark, D., Hanafi, S., Gibson, W., Wagg, A., Tanel, M., Laing, A., Weaver, T., Lupo, J., Giangregorio, L., Payne, A., Sheets, D., Beach, C., Elliott, J., Stolee, P., Stinchcombe, A., Bédard, M., Enright, J., Wilson, K., Ozen, L., Silman, J., Gibbons, C., McKinnon, T., Timble, J., Willison, K., Boland, L., Perez, M. Margarita Becerra, McIsaac, D., Edmond, J., Brown, K., Leigh, J. Parsons, Buchner, D., Stelfox, H. T., Aziz, J., Crake, D., Ren, Z., Grant, T., Goubran, R., Knoefel, F., Sveistrup, H., Bilodeau, M., Oliver, J., Chidwick, P., Booi, L., Magyar, T., Martin, M., Ko, J. Hyun, Shannon, J., Wilson-Pease, E., Kephart, G., Babin, N., Malik, H., Maximos, M., Seng, S., Vandenberg, G., Dal Bello-Haas, V., Lagrotteria, A., Sullivan, K., Mihaylova, A., Lu, C., Koh, J., Hamielec, C., Steer, M., Jimenez, C., Woo, K., Julian, P., Martin, L. Schindel, McLelland, V., Ryan, D., Wilding, L., Chang, C. E., van Schooten, K. S, Wong, F., Robinovitch, S. N, Balasubramanaiam, B., Chenkin, J., Snider, T. G., Melady, D., Lee, J. S., Petrella, A., Heath, M., Shellington, E., Laguë, A., Voyer, P., Ouellet, M., Boucher, V., Pelletier, M., Gouin, É., Daoust, R., Berthelot, S., Giroux, M., Sirois, M., Émond, M., Bergstrom, V., Tate, K., Lee, S., Reid, C., Rowe, B., Cummings, G., Holroyd-Leduc, J., El-Bialy, R., Zhao, B., Baumbusch, J., Busson, C., Kohr, R., Donovan, J., Philpott, K., Kingston, J., Rickards, T., Weiler, C., Lanovaz, J., Arnold, C., Chiu, K., Cuperfain, A., Zhu, K., Zhao, X., Zhao, S., Iaboni, A., Perrella, A., Chau, V., Hu, C. Dong, Farooqi, M., Patel, S., Bauer, J., Lee, L., Schill, C., Patel, T., Mroz, L., Kryworuchko, J., Carter, R., Spencer, L., Barwich, D., Roy, N., Després, C., Leyenaar, M., McLeod, B., Poss, J., Costa, A., Blums, J., Costa, I. Geraldina, Tregunno, D., Kirkham, J., Seitz, D., Velkers, C., Krawczyk, M., Garland, E., Michaud, M., Pakzad, S., Bourque, P. E., Eamer, G., Gibson, J. A, Gillis, C., Hsu, A. T, MacDonald, E., Whitlock, R., Khadaroo, R. G, Brisebois, R., Clement, F., Hathaway, J., Bagheri, Z. S., Costa, I. G., Schinkel-Ivy, A., Rodney, P. (Paddy), Varcoe, C., Jiwani, B., Fenton, T., Gramlich, L., Tangri, N., Eng, F., Bohm, C., Komenda, P., Rigatto, C., Brar, R., McCloskey, R., Keeping-Burke, L., Donovan, C., Verma, A., Razak, F., Kwan, J., Lapointe-Shaw, L., Rawal, S., Tang, T., Weinerman, A., Guo, Y., Mamdani, M., McNicholl, T., Valaitis, R., Tarraf, R., Boakye, O., Suter, E., Boulanger, P., Birney, A., Sadowski, C. A, Gill, G., Mrklas, K., Plaisance, A., Noiseux, F., Francois, R., LeBlanc, A., McGinn, C. A., Tapp, D., Archambault, P. M., Begum, J., Wikjord, N., Roy, P., Reimer-Kirkham, S., Doane, G., Hilliard, N., Giesbrech, M., Dujela, C., Harerimana, B., Forchuk, C., Booth, R., Vasudev, A., Isaranuwatchai, W., Seth, P., Ramsey, D., Rudnick, A., Heisel, M., Reiss, J., Lee, E., Mate, K., Aubertin-Leheude, M., Fiore, J., Auais, M., Moriello, C., Scott, S., Wilson, M., McDonald, E., Lee, T., Arora, N., Hanvey, L., Elston, D., Heyland, R., Heyland, D., Langevin, J., Fang, Q., Price, D., Nowak, C., Fang, H., Richardson, J., Phillips, S., Gordon, C., Xie, F., Adachi, J., Tang, A., Swinton, M., Winhall, M., Clark, B., Sinuff, T., Abelson, J., You, J., Shears, M., Takaoka, A., Tina, M., Amanda, H., Surenthar, T., Li, G., Rochwerg, B., Woo, T., Bagshaw, S., Johnstone, J., Cook, D., Beaton, D., Drance, E., Leblanc, M.E., O’Connor, D., Ono, E., Phinney, A., Reid, R. C., Rodney, P. A., Tait, J., Ward-Griffin, C., Millen, T., Clarke, F., Thabane, L., Dogba, M. J., Rivest, L.l, Durand, P. J., Fraser, K., Bourassa, H., Embuldeniya, G., Farmanova, E., Auguste, D., Witteman, H. O, Kröger, E., Beaulieu, É., MC Giguere, A., Paragg, J., Swindle, J., Webber, T., Porterfield, P., Husband, A., Kryworucko, J., Trenaman, L., Bryan, S., Cuthbertson, L., Bansback, N., de Grood, C., Dodek, P., Fowler, R., Forster, A., Boyd, J., Stelfox, H., Kruger, S., Steinberg, M., Quinn, K., Yarnell, C., Fu, L., Manuel, D., Tanuseputro, P., Stukel, T., Pinto, R., Scales, D., Laupacis, A., Varughese, R., Huang, A., Famure, O., Chowdhury, N., Renner, E., Kim, J., MacIver, J., Singer, L., Gali, B., Brewster, P., Asche, C., Mitz, A., Hundza, S., MacDonald, S., Kaechele, N., Donald, E., Kaur, S., Fernandes, P., Pauloff, K., Gordon, A., Kallan, L., Grinman, M., Human, T., Ying, I., Pattullo, A., Wong, H., Feldman, S., Moffat, D., Zjadewicz, K., McIntosh, C. J., Alghamdi, M., McComb, A., Ferrone, A., Geng, W., Weeks-Levy, C., and Menon, C.
- Subjects
Abstracts ,Canadian Frailty Network Abstracts from the Meeting in Toronto, September 27–29, 2015 ,Canadian Frailty Network Abstracts from the Meeting Held in Toronto, April 23–24, 2017 - Published
- 2017
3. RELIABILITY OF NURSES' USE OF A DIRECT BEHAVIOURAL OBSERVATION TOOL IN THE DEMENTIA CONTEXT: IMPLICATIONS FOR DEVELOPMENT OF PREDICTIVE SYSTEMS OF BEHAVIOURAL ASSESSMENT.
- Author
-
Newman, K., Martin, L. Schindel, McLelland, V., Wang, A., Au Duong, J., Khan, S. S., Ye, B., Spasojevic, S., Iaboni, A., and Mihailidis, A.
- Published
- 2021
4. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
- Author
-
Chaturvedi, N, Stevenson, J, Fuller, Jh, Rottiers, R, Ferriss, B, Karamanos, B, Kofinis, A, Petrou, C, Ionescutirgovisite, C, Iosif, C, Tamas, G, Bibok, G, Kerenyi, Z, Kisgombos, P, Toth, J, Grealy, G, Priem, H, Koivisto, V, Tuominen, J, Kostamo, E, Idziorwalus, B, Solnica, B, Galickalatalie, D, Michel, G, Keipes, M, Giuliani, A, Herode, A, Santeusanio, F, Bueti, A, Bistoni, S, Cagini, Navalesi, R, Penno, G, Nannipieri, Monica, Rizzo, L, Miccoli, Roberto, Ghirlanda, G, Cotroneo, P, Manto, A, Minella, A, Saponara, C, Ward, J, Plater, M, Ibrahim, S, Ibbotson, S, Mody, C, Papazoglou, N, Manes, C, Soulis, K, Voukias, M, Muggeo, M, Cacciatori, V, Gemma, Ml, Dellera, A, Castellarin, A, Irsigler, K, Abrahamian, H, Gurdet, C, Willinger, C, Nelstrop, A, Feben, C, Walford, S, Mclelland, V, Hughes, S, Metelko, Z, Roglic, G, Pepeonik, Zr, Stephenson, J, Viberti, Gc, Sjolie, Ak, Holloway, J, Milne, M, Webb, D, Bulpitt, C, Fletcher, A, Shipley, M, John, G, and Newman, Dj
- Subjects
medicine.medical_specialty ,Proteinuria ,endocrine system diseases ,business.industry ,Urology ,Lisinopril ,Renal function ,Captopril ,General Medicine ,urologic and male genital diseases ,Placebo ,medicine.disease ,Endocrinology ,Internal medicine ,ACE inhibitor ,medicine ,Albuminuria ,Microalbuminuria ,medicine.symptom ,business ,medicine.drug - Abstract
Summary Background Renal disease in people with insulin-dependent diabetes (IDDM) continues to pose a major health threat. Inhibitors of angiotensin-converting enzyme (ACE) slow the decline of renal function in advanced renal disease, but their effects at earlier stages are unclear, and the degree of albuminuria at which treatment should start is not known. Methods We carried out a randomised, double-blind, placebo-controlled trial of the ACE inhibitor lisinopril in 530 men and women with IDDM aged 20–59 years with normoalbuminuria or microalbuminuria. Patients were recruited from 18 European centres, and were not on medication for hypertension. Resting blood pressure at entry was at least 75 and no more than 90 mm hg diastolic, and no more than 155 mm hg systolic. Urinary albumin excretion rate (AER) was centrally assessed by means of two overnight urine collections at baseline, 6, 12, 18, and 24 months. Findings There were no differences in baseline characteristics by treatment group; mean AER was 8.0 μg/min in both groups; and prevalence of microalbuminuria was 13% and 17% in the placebo and lisinopril groups, respectively. On intention-to-treat analysis at 2 years, AER was 2.2 μg/min lower in the lisinopril than in the placebo group, a percentage difference of 18.8% (95% CI 2·0–32·7, p=0·03), adjusted for baseline AER and centre, absolute difference 2.2 μg/min. In people with normoalbuminuria, the treatment difference was 1·0 μg/min (12·7% [−2·9 to 26·0], p=0·1). In those with microalbuminuria, however, the treatment difference was 34.2 μg/min (49·7% [−14·5 to 77·9], p=0·1; for interaction, p=0·04). For patients who completed 24 months on the trial, the final treatment difference in AER was 38·5 μg/min in those with microalbuminuria at baseline (p=0·001), and 0·23 μg/min in those with normoalbuminuria at baseline (p=0·6). There was no treatment difference in hypoglycaemic events or in metabolic control as assessed by glycated haemoglobin. Interpretation Lisinopril slows the progression of renal disease in normotensive IDDM patients with little or no albuminuria, though greatest effect was in those with microalbuminuria (AER ≥20 μg/min). Our results show that lisinopril does not increase the risk of hypoglycaemic events in IDDM.
- Published
- 1997
- Full Text
- View/download PDF
5. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: The EURODIAB Prospective Complications Study
- Author
-
Peeters, S. A., Engelen, L., Buijs, J., Chaturvedi, N., Fuller, J. H., Schalkwijk, C. G., Stehouwer, C. D., Karamanos, B., Kofinis, A., Petrou, K., Giorgino, F., Picca, G., Angarano, A., De, Pergola. G., Laviola, L., Giorgino, R., Ionescu-Tirgoviste, C., Coszma, A., Guja, C., Songini, M., Casu, A., Pedron, M., Pintus, S., Fossarello, M., Ferriss, J. B., Grealy, G., O'Keefe, D., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Koivisto, V. A., Idzior-Walus, B., Sieradzki, J., Cyganek, K., Solnica, B., Lemkes, H. H. P. J., Lemkes-Stuffken, J. C., Nunes-Correa, J., Rogado, M. C., Gardete-Correia, L., Cardoso, M. C., Silva, A., Boavida, J., Machado Sa Marques, M., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, M., Verier-Mine, O., Fallas, P., Fallas, M. C., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D'Alessandro, V., Cagini, C., Bottini, P., Reboldi, G. P., Navalesi, R., Penno, G., Bandinelli, S., Miccoli, R., Nannipieri, M., Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, Andrea, Minnella, Angelo Maria, Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Borra, M., Cavallo Perin, P., Giunti, S., Grassi, G., Pagano, G. F., Porta, M., Sivieri, R., Vitelli, F., Veglio, M., Papazoglou, N., Manes, G., Muggeo, M., Iagulli, M., Cacciatori, V., Cattedra di Malattie del Metabolismo, V., Irsigler, K., Abrahamian, H., Walford, S., Sinclair, J., Hughes, S., Mclelland, V., Ward, J., Roglic, G., Metelko, Z., Pepeonik, Z. R., Manto A., Minnella A. (ORCID:0000-0001-5896-5313), Peeters, S. A., Engelen, L., Buijs, J., Chaturvedi, N., Fuller, J. H., Schalkwijk, C. G., Stehouwer, C. D., Karamanos, B., Kofinis, A., Petrou, K., Giorgino, F., Picca, G., Angarano, A., De, Pergola. G., Laviola, L., Giorgino, R., Ionescu-Tirgoviste, C., Coszma, A., Guja, C., Songini, M., Casu, A., Pedron, M., Pintus, S., Fossarello, M., Ferriss, J. B., Grealy, G., O'Keefe, D., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Koivisto, V. A., Idzior-Walus, B., Sieradzki, J., Cyganek, K., Solnica, B., Lemkes, H. H. P. J., Lemkes-Stuffken, J. C., Nunes-Correa, J., Rogado, M. C., Gardete-Correia, L., Cardoso, M. C., Silva, A., Boavida, J., Machado Sa Marques, M., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, M., Verier-Mine, O., Fallas, P., Fallas, M. C., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D'Alessandro, V., Cagini, C., Bottini, P., Reboldi, G. P., Navalesi, R., Penno, G., Bandinelli, S., Miccoli, R., Nannipieri, M., Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, Andrea, Minnella, Angelo Maria, Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Borra, M., Cavallo Perin, P., Giunti, S., Grassi, G., Pagano, G. F., Porta, M., Sivieri, R., Vitelli, F., Veglio, M., Papazoglou, N., Manes, G., Muggeo, M., Iagulli, M., Cacciatori, V., Cattedra di Malattie del Metabolismo, V., Irsigler, K., Abrahamian, H., Walford, S., Sinclair, J., Hughes, S., Mclelland, V., Ward, J., Roglic, G., Metelko, Z., Pepeonik, Z. R., Manto A., and Minnella A. (ORCID:0000-0001-5896-5313)
- Published
- 2015
6. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study
- Author
-
Peeters, Stijn A., Engelen, Lian, Buijs, Jacqueline, Chaturvedi, Nish, Fuller, John H., Schalkwijk, Casper G., Stehouwer, Coen D, Karamanos, B., Kofinis, A., Petrou, K., Giorgino, F., Picca, G., Angarano, A., Null, de P. e. r. g. o. l. a. G., Laviola, L., Giorgino, R., Ionescu Tirgoviste, C., Coszma, A., Guja, C., Songini, M., Casu, A., Pedron, M., Pintus, S., Fossarello, M., Ferriss, J. B., Grealy, G., O'Keefe, D., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Koivisto, V. A., Idzior Walus, B., Sieradzki, J., Cyganek, K., Solnica, B., Lemkes, H. H. P. J., Lemkes Stuffken, J. C., Nunes Correa, J., Rogado, M. C., Gardete Correia, L., Cardoso, M. C., Silva, A., Boavida, J., Machado Sa Marques, M., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, M., Verier Mine, O., Fallas, P., Fallas, M. C., Fuller, J. H., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D'Alessandro, V., Cagini, C., Bottini, P., Reboldi, G. P., Navalesi, R., Penno, Giuseppe, Bandinelli, S., Miccoli, Roberto, Nannipieri, Monica, Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, A., Minnella, A., Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Borra, M., Cavallo Perin, P., Giunti, S., Grassi, G., Pagano, G. F., Porta, M., Sivieri, R., Vitelli, F., Veglio, M., Papazoglou, N., Manes, G., Muggeo, M., Iagulli, M., Cacciatori, V., Cattedra di Malattie del Metabolismo, V., Irsigler, K., Abrahamian, H., Walford, S., Sinclair, J., Hughes, S., Mclelland, V., Ward, J., Roglic, G., Metelko, Z., Pepeonik, Z. R., Clinicum, Department of Medicine, Interne Geneeskunde, MUMC+: MA Interne Geneeskunde (3), and RS: CARIM - R3 - Vascular biology
- Subjects
Male ,Endocrinology, Diabetes and Metabolism ,Matrix metalloproteinase ,Gastroenterology ,Cohort Studies ,Endocrinology ,Prospective Studies ,Endothelial dysfunction ,Original Investigation ,Settore MED/30 - MALATTIE APPARATO VISIVO ,Middle Aged ,Cardiovascular disease ,3. Good health ,Europe ,Diabetes and Metabolism ,Albuminuria ,Retinopathy ,Tissue inhibitor of metalloproteinase ,Type 1 diabetes ,Adult ,Biomarkers ,Cross-Sectional Studies ,Diabetes Complications ,Diabetes Mellitus, Type 1 ,Female ,Humans ,Matrix Metalloproteinase 10 ,Matrix Metalloproteinase 2 ,Matrix Metalloproteinase 3 ,Tissue Inhibitor of Metalloproteinase-1 ,Vascular Diseases ,Cardiology and Cardiovascular Medicine ,medicine.symptom ,Type 1 ,medicine.medical_specialty ,education ,Inflammation ,Diabetes mellitus ,Internal medicine ,medicine ,Diabetes Mellitus ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,medicine.disease ,3121 General medicine, internal medicine and other clinical medicine ,business - Abstract
Background Impaired regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in patients with type 1 diabetes. We investigated associations between plasma MMP-1, −2, −3, −9, −10 and TIMP-1, and cardiovascular disease (CVD) or microvascular complications in type 1 diabetic patients. We also evaluated to which extent these associations could be explained by low-grade inflammation (LGI) or endothelial dysfunction (ED). Methods 493 type 1 diabetes patients (39.5 ± 9.9 years old, 51% men) from the EURODIAB Prospective Complications Study were included. Linear regression analysis was applied to investigate differences in plasma levels of MMP-1, −2, −3, −9, −10, and TIMP-1 between patients with and without CVD, albuminuria or retinopathy. All analyses were adjusted for age, sex, duration of diabetes, Hba1c and additionally for other cardiovascular risk factors including LGI and ED. Results Patients with CVD (n = 118) showed significantly higher levels of TIMP-1 [β = 0.32 SD (95%CI: 0.12; 0.52)], but not of MMPs, than patients without CVD (n = 375). Higher plasma levels of MMP-2, MMP-3, MMP-10 and TIMP-1 were associated with higher levels of albuminuria (p-trends were 0.028, 0.004, 0.005 and 0.001, respectively). Severity of retinopathy was significantly associated with higher levels of MMP-2 (p-trend = 0.017). These associations remained significant after further adjustment for markers of LGI and ED. Conclusions These data support the hypothesis that impaired regulation of matrix remodeling by actions of MMP-2, -3 and-10 and TIMP-1 contributes to the pathogenesis of vascular complications in type 1 diabetes. Electronic supplementary material The online version of this article (doi:10.1186/s12933-015-0195-2) contains supplementary material, which is available to authorized users.
- Full Text
- View/download PDF
7. Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland.
- Author
-
Vedi A, Leiter SM, Memon IL, Mahendrayogam A, Van Rijswijk E, Uparkar U, Shenton G, Trinquand A, Clesham K, McLelland V, Campbell H, Patrick K, Thompson L, Baird S, Connor P, Lancaster D, and James B
- Subjects
- Humans, Child, Female, Male, United Kingdom epidemiology, Child, Preschool, Adolescent, Ireland epidemiology, Infant, Leukemia, Promyelocytic, Acute drug therapy, Leukemia, Promyelocytic, Acute mortality, Leukemia, Promyelocytic, Acute genetics, Leukemia, Promyelocytic, Acute diagnosis, Arsenic Trioxide therapeutic use, Arsenic Trioxide administration & dosage, Tretinoin therapeutic use, Tretinoin administration & dosage
- Abstract
Acute promyelocytic leukaemia (APL), defined by the t(15;17)(q24;q21) translocation, accounts for 5%-10% of paediatric acute myeloid leukaemia cases. All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are key treatments, though ATO access varies. We evaluated treatment, complications and survival in 50 UK paediatric APL patients diagnosed between 2014 and 2021. All patients received ATRA and most received ATO. Event-free survival was lower in high-risk patients (85% vs. 100%, p = 0.03), and those not receiving ATO at diagnosis. All relapsed patients could be salvaged with ATO. Addressing ATO availability and consistent funding is crucial to ensure timely treatment and improve outcomes., (© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2025
- Full Text
- View/download PDF
8. An Education Intervention to Enhance Staff Self-Efficacy to Provide Dementia Care in an Acute Care Hospital in Canada: A Nonrandomized Controlled Study.
- Author
-
Schindel Martin L, Gillies L, Coker E, Pizzacalla A, Montemuro M, Suva G, and McLelland V
- Subjects
- Canada, Follow-Up Studies, Humans, Person-Centered Psychotherapy, Dementia nursing, Personnel, Hospital education, Self Efficacy
- Abstract
Education is needed for enhanced capacity of acute hospitals to provide dementia care. A nonrandomized controlled, repeated-measures design was used to evaluate a dementia education program delivered to an intervention group (IG, n = 468), compared to a wait-listed group (n = 277), representing separate sites of a multisite hospital. Participants completed self-efficacy for dementia and satisfaction measures and provided written descriptions of dementia care collected at baseline, postintervention (IG only), and at 8-week follow-up. Oral narratives were gathered from IG participants 8 weeks postintervention. The IG demonstrated significant improvement in self-efficacy scores from baseline to immediately postintervention (P < .001), sustained at 8 weeks. There were no changes from baseline to 8 weeks postintervention evident in the wait-listed group (P = .21). Intervention group participants described positive impacts including implementation of person-centered care approaches. Implementation of dementia care education programs throughout hospital settings is promising for the enhancement of dementia care., (© The Author(s) 2016.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.